title: Effect of pravastatin on the survival of patients with advanced gastric cancer.
abstract: OBJECTIVE
  A fluoropyrimidine plus cisplatin combined with surgery is standard first-line treatment for advanced gastric cancer. We evaluated the effect of pravastatin on overall survival in patients with advanced gastric cancer in a prospective cohort study.
  
  
  METHODS
  At the time of surgery, we assigned 60 patients with advanced gastric cancer (stage III or IV) to receive standard first-line treatment (control group) or standard first-line treatment plus pravastatin at a dose of 40 mg once daily (pravastatin group). The minimum follow-up period was 4 years and the maximum of 6 years.
  
  
  RESULTS
  The mean of age was 66 years and the TNM stage was III and IV in 65% and 35% of patients, respectively. There was no significant difference between the two groups (control vs pravastatin) in median overall survival (15 vs 14 months; P = 0.8). Predictors of survival were the stage (hazard ratio of death stage IV (III stage as reference): 4.4; 95% CI: 2-9.7; p < 0.05) and older age (hazard ratio of death ≥ 65 years (< 65 years as reference): 2.8; 95% CI: 1.3-6; p < 0.05).
  
  
  CONCLUSIONS
  Pravastatin did not improve outcome in patients with advanced gastric cancer.
authors.affiliation: Department of Gastroenterology, Donostia University Hospital, Biodonostia Health Research Institute, University of the Basque Country (UPV/EHU), IKERBASQUE, AECC, San Sebastián, Spain.|National Institute for The Study of Liver and Gastrointestinal Diseases (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
authors.forename: Luis
authors.initials: L
authors.lastname: Bujanda
authors.affiliation: Department of Surgery, Donostia University Hospital, Biodonostia Health Research Institute, University of the Basque Country (UPV/EHU), San Sebastián, Spain.
authors.forename: Araceli
authors.initials: A
authors.lastname: Rodríguez-González
authors.affiliation: Donostia University Hospital, Biodonostia Health Research Institute, Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), San Sebastián, Spain.
authors.forename: Cristina
authors.initials: C
authors.lastname: Sarasqueta
authors.affiliation: Department of Surgery, Donostia University Hospital, Biodonostia Health Research Institute, University of the Basque Country (UPV/EHU), San Sebastián, Spain.
authors.forename: Emma
authors.initials: E
authors.lastname: Eizaguirre
authors.affiliation: Department of Gastroenterology, Donostia University Hospital, Biodonostia Health Research Institute, University of the Basque Country (UPV/EHU), IKERBASQUE, AECC, San Sebastián, Spain.|National Institute for The Study of Liver and Gastrointestinal Diseases (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Hijona
authors.affiliation: Experimental Hepatology and Drug Targeting (HEVEFARM), Biomedical Research Institute of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain.|National Institute for The Study of Liver and Gastrointestinal Diseases (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
authors.forename: José J G
authors.initials: JJ
authors.lastname: Marín
authors.affiliation: Department of Gastroenterology, Donostia University Hospital, Biodonostia Health Research Institute, University of the Basque Country (UPV/EHU), IKERBASQUE, AECC, San Sebastián, Spain.|National Institute for The Study of Liver and Gastrointestinal Diseases (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
authors.forename: María J
authors.initials: MJ
authors.lastname: Perugorria
authors.affiliation: Department of Gastroenterology, Donostia University Hospital, Biodonostia Health Research Institute, University of the Basque Country (UPV/EHU), IKERBASQUE, AECC, San Sebastián, Spain.|National Institute for The Study of Liver and Gastrointestinal Diseases (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
authors.forename: Jesús M
authors.initials: JM
authors.lastname: Banales
authors.affiliation: Department of Gastroenterology, Donostia University Hospital, Biodonostia Health Research Institute, University of the Basque Country (UPV/EHU), IKERBASQUE, AECC, San Sebastián, Spain.
authors.forename: Angel
authors.initials: A
authors.lastname: Cosme
mesh_terms: D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D009367:Neoplasm Staging; D017035:Pravastatin / Q000627:therapeutic use*; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D015996:Survival Rate
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017035:Pravastatin
keywords: advanced; gastric cancer; overall survival; pravastatin